Cross-source consensus on what matters today in genetics and genomics — drawn from 16 trusted public sources including NHGRI, the CDC, NHS England, Genomics England, the PHG Foundation, the Wellcome Sanger Institute, and peer-reviewed open-access journals.
Last updated: · browse archive
The US Food and Drug Administration has reversed its earlier opposition, allowing UniQure to file its investigational RNA-interference treatment for Huntington's disease for regulatory review.
Cancer Research UK reports that new data provide the strongest evidence to date that the UK HPV vaccination programme is reducing not only cervical cancer incidence but cervical cancer mortality.
A preprint from Cold Spring Harbor Laboratory applies saturation genome editing to reclassify more than 9,000 variants of uncertain significance in two hereditary cancer genes.
A PLOS Genetics study from researchers at Children's National Hospital and the Stowers Institute provides the largest functional dataset to date for variants in ASS1, the gene disrupted in citrullinaemia type I, and reveals unexpected epistatic interactions between variants.
A GPU-accelerated reimplementation of the coloc algorithm, published in PLOS Genetics, makes it feasible to test colocalisation across millions of association signals from large biobanks and molecular QTL studies.
Researchers report that somatic mutations associated with haematological malignancies could trigger neuroinflammation implicated in Alzheimer's disease, suggesting a previously unrecognised mechanistic overlap between the two conditions.
The world's first randomised trial of a multi-cancer early detection blood test did not meet its primary endpoint, though commentators argue the results carry important signals for the field of early-detection genomics.
A preprint reports that in vivo CRISPR editing targeting the mismatch repair gene Msh3 slowed somatic CAG repeat expansion and mitigated disease pathology in a Huntington's disease mouse model.
A preprint from Cold Spring Harbor Laboratory describes a 'dish-to-biobank' framework that connects controlled glucolipotoxicity stress in stem-cell-derived beta cells to population-scale type 2 diabetes genetics via the plasma proteome.
Phase 3 results for Revolution Medicines' daraxonrasib show a 60% reduction in risk of death compared with standard chemotherapy, marking the first practice-changing advance for KRAS-mutant pancreatic cancer.
About Genetic Current
Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.
Join the Evagene Alpha Waiting List